In a phase 2 trial of patients with castration-resistant and neuroendocrine prostate cancer, a subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit from single-agent alisertib (31). Here, MYCN is linked to prostate cancer.